Bone marrow neoplastic niche in leukemia

References

• Borovski T, De Sousa EMF, Vermeulen L, Medema JP. Cancer stem cell niche: the place to be. Cancer Res. [Research Support, Non-U.S. Gov't Review] 2011;71(3):634–9.
   Google Scholar
• Saki N, Abroun S, Hagh MF, Asgharei F. Neoplastic bone marrow niche: hematopoietic and mesenchymal stem cells. Cell 2011;13(3):131–6.
   PubMed Web of Science ®Google Scholar
• Konopleva MY, Jordan CT. Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Review] 2011;29(5):591–9.
   Google Scholar
• Colmone A, Amorim M, Pontier AL, Wang S, Jablonski E, Sipkins DA. Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Science [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't] 2008;322(5909):1861–5.
   Google Scholar
• Ehninger A, Trumpp A. The bone marrow stem cell niche grows up: mesenchymal stem cells and macrophages move in. J Exp Med. [Research Support, Non-U.S. Gov't Review] 2011;208(3):421–8.
   Web of Science ®Google Scholar
• Shen Y, Nilsson SK. Bone, microenvironment and hematopoiesis. Curr Opin Hematol. [Review] 2012;19(4):250–5.
   PubMed Web of Science ®Google Scholar
• Li L, Neaves WB. Normal stem cells and cancer stem cells: the niche matters. Cancer Res. [Comparative Study Review] 2006;66(9):4553–7.
   PubMed Web of Science ®Google Scholar
• Haramis AP, Begthel H, van den Born M, van Es J, Jonkheer S, Offerhaus GJ, et al. De novo crypt formation and juvenile polyposis on BMP inhibition in mouse intestine. Science 2004;303(5664):1684–6.
   PubMed Web of Science ®Google Scholar
• He XC, Zhang J, Tong WG, Tawfik O, Ross J, Scoville DH, et al. BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt-beta-catenin signaling. Nat Genet. [Research Support, Non-U.S. Gov't] 2004;36(10):1117–21.
   Google Scholar
• Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.] 2004;351(7):657–67.
   Web of Science ®Google Scholar
• Paydas S, Tanriverdi K, Yavuz S, Disel U, Sahin B, Burgut R. Survivin and aven: two distinct antiapoptotic signals in acute leukemias. Ann Oncol. [Comparative Study] 2003;14(7):1045–50.
   PubMed Web of Science ®Google Scholar
• Tzifi F, Economopoulou C, Gourgiotis D, Ardavanis A, Papageorgiou S, Scorilas A. The role of BCL2 family of apoptosis regulator proteins in acute and chronic leukemias. Adv Hematol. 2012; doi: 10.1155/2012/524308.
   PubMedGoogle Scholar
• Irmisch A, Huelsken J. Metastasis: New insights into organ-specific extravasation and metastatic niches. Exp Cell Res. 2013;319(11):1604–10.
   PubMed Web of Science ®Google Scholar
• Descot A, Oskarsson T. The molecular composition of the metastatic niche. Exp Cell Res. 2013;319(11):1679–86.
   PubMed Web of Science ®Google Scholar
• Nwajei F, Konopleva M. The bone marrow microenvironment as niche retreats for hematopoietic and leukemic stem cells. Adv Hematol. 2013; doi: 10.1155/2013/953982.
   PubMedGoogle Scholar
• Krause DS, Lazarides K, von Andrian UH, Van Etten RA. Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat Med. [Research Support, N.I.H., Extramural] 2006;12(10):1175–80.
   PubMed Web of Science ®Google Scholar
• Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med. [Research Support, Non-U.S. Gov't] 2006;12(10):1167–74.
   Google Scholar
• Meads MB, Hazlehurst LA, Dalton WS. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res. [Review] 2008;14(9):2519–26.
   PubMed Web of Science ®Google Scholar
• Raaijmakers MH. ATP-binding-cassette transporters in hematopoietic stem cells and their utility as therapeutical targets in acute and chronic myeloid leukemia. Leukemia. [Review] 2007;21(10):2094–102.
   PubMed Web of Science ®Google Scholar
• de Jonge-Peeters SD, Kuipers F, de Vries EG, Vellenga E. ABC transporter expression in hematopoietic stem cells and the role in AML drug resistance. Crit Rev Oncol Hematol. [Research Support, Non-U.S. Gov't Review] 2007;62(3):214–26.
   PubMed Web of Science ®Google Scholar
• Colombo M, Mirandola L, Platonova N, Apicella L, Basile A, Figueroa AJ, et al. Notch-directed microenvironment reprogramming in myeloma: a single path to multiple outcomes. Leukemia 2013;27(5):1009–18.
   PubMed Web of Science ®Google Scholar
• Wang JC, Dick JE. Cancer stem cells: lessons from leukemia. Trends Cell Biol. [Review] 2005;15(9):494–501.
   PubMed Web of Science ®Google Scholar
• Hu Y, Fu L. Targeting cancer stem cells: a new therapy to cure cancer patients. Am J Cancer Res. 2012;2(3):340–56.
   PubMed Web of Science ®Google Scholar
• Kaplan RN, Psaila B, Lyden D. Niche-to-niche migration of bone-marrow-derived cells. Trends Mol Med. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review] 2007;13(2):72–81.
   Google Scholar
• Govindan R, Kumar V, Sisodia S, Mallick PJ. Molecular interactions in stem cell homing and bone marrow transplantation therapy. Int J Pharm. 2012;3(4):210–3.
   Google Scholar
• Bonig H, Priestley GV, Papayannopoulou T. Hierarchy of molecular-pathway usage in bone marrow homing and its shift by cytokines. Blood. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't] 2006;107(1):79–86.
   Google Scholar
• Papayannopoulou T, Priestley GV, Nakamoto B, Zafiropoulos V, Scott LM. Molecular pathways in bone marrow homing: dominant role of alpha(4)beta(1) over beta(2)-integrins and selectins. Blood. 2001;98(8):2403–11.
   PubMed Web of Science ®Google Scholar
• Guzman ML, Jordan CT. Considerations for targeting malignant stem cells in leukemia. Cancer Control. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review] 2004;11(2):97–104.
   Google Scholar
• Deng CH, Zhang QP. Leukemia stem cells in drug resistance and metastasis. Chin Med J (Engl). [Research Support, Non-U.S. Gov't Review] 2010;123(7):954–60.
   Google Scholar
• O'Hare T, Corbin AS, Druker BJ. Targeted CML therapy: controlling drug resistance, seeking cure. Curr Opin Genet Dev. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review] 2006;16(1):92–9.
   Google Scholar
• O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. [Research Support, Non-U.S. Gov't] 2009;16(5):401–12.
   Google Scholar
• Swerts K, De Moerloose B, Dhooge C, Laureys G, Benoit Y, Philippe J. Prognostic significance of multidrug resistance-related proteins in childhood acute lymphoblastic leukaemia. Eur J Cancer. [Research Support, Non-U.S. Gov't Review] 2006;42(3):295–309.
   PubMed Web of Science ®Google Scholar
• Fleming HE, Janzen V, Lo Celso C, Guo J, Leahy KM, Kronenberg HM, et al. Wnt signaling in the niche enforces hematopoietic stem cell quiescence and is necessary to preserve self-renewal in vivo. Cell Stem Cell. [Research Support, N.I.H., Extramural] 2008;2(3):274–83.
   PubMed Web of Science ®Google Scholar
• Kim Y, Thanendrarajan S, Schmidt-Wolf IG. Wnt/ss-catenin: a new therapeutic approach to acute myeloid leukemia. Leuk Res Treatment. 2011; doi: 10.4061/2011/428960.
   Google Scholar
• Rizo A, Vellenga E, de Haan G, Schuringa JJ. Signaling pathways in self-renewing hematopoietic and leukemic stem cells: do all stem cells need a niche? Hum Mol Genet. [Research Support, Non-U.S. Gov't Review] 2006;15(2):R210–9.
   PubMedGoogle Scholar
• Weber JM, Calvi LM. Notch signaling and the bone marrow hematopoietic stem cell niche. Bone [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review] 2010;46(2):281–5.
   Google Scholar
• Schepers K, Hsiao EC, Garg T, Scott MJ, Passegue E. Activated Gs signaling in osteoblastic cells alters the hematopoietic stem cell niche in mice. Blood [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't] 2012;120(17):3425–35.
   Google Scholar
• Abroun S, Saki N, Fakher R, Asghari F. Biology and bioinformatics of myeloma cell. Lab Hematol. 2012;18(4):30–41.
   PubMedGoogle Scholar
• Noll JE, Williams SA, Purton LE, Zannettino AC. Tug of war in the haematopoietic stem cell niche: do myeloma plasma cells compete for the HSC niche? Blood Cancer J. 2012;2:e91.
   PubMed Web of Science ®Google Scholar
• Roman-Gomez J, Cordeu L, Agirre X, Jimenez-Velasco A, San Jose-Eneriz E, Garate L, et al. Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia. Blood [Clinical Trial Comparative Study Multicenter Study Research Support, Non-U.S. Gov't Retracted Publication] 2007;109(8):3462–9.
   Google Scholar
• Thanendrarajan S, Kim Y, Schmidt-Wolf IG. Understanding and Targeting the Wnt/beta-Catenin Signaling Pathway in Chronic Leukemia. Leuk Res Treatment. 2011; doi: 10.4061/2011/329572.
   Google Scholar
• Rosenbauer F, Koschmieder S, Steidl U, Tenen DG. Effect of transcription-factor concentrations on leukemic stem cells. Blood. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. Review] 2005;106(5):1519–24.
   Google Scholar
• Gao SM, Xing CY, Chen CQ, Lin SS, Dong PH, Yu FJ. miR-15a and miR-16-1 inhibit the proliferation of leukemic cells by down-regulating WT1 protein level. J Exp Clin Cancer Res. [Research Support, Non-U.S. Gov't] 2011;30:110.
   PubMed Web of Science ®Google Scholar
• Helbling D, Mueller BU, Timchenko NA, Hagemeijer A, Jotterand M, Meyer-Monard S, et al. The leukemic fusion gene AML1-MDS1-EVI1 suppresses CEBPA in acute myeloid leukemia by activation of Calreticulin. Proc Natl Acad Sci USA. [Research Support, Non-U.S. Gov't] 2004;101(36):13312–7.
   PubMed Web of Science ®Google Scholar
• Perrotti D, Cesi V, Trotta R, Guerzoni C, Santilli G, Campbell K, et al. BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2. Nat Genet. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.] 2002;30(1):48–58.
   Google Scholar
• Helbling D, Mueller BU, Timchenko NA, Schardt J, Eyer M, Betts DR, et al. CBFB-SMMHC is correlated with increased calreticulin expression and suppresses the granulocytic differentiation factor CEBPA in AML with inv(16). Blood. [Research Support, Non-U.S. Gov't] 2005;106(4):1369–75.
   Google Scholar
• Zhang P, Zhang X, Iwama A, Yu C, Smith KA, Mueller BU, et al. PU.1 inhibits GATA-1 function and erythroid differentiation by blocking GATA-1 DNA binding. Blood [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.] 2000;96(8):2641–8.
   Google Scholar
• Ohnishi K. PML-RARalpha inhibitors (ATRA, tamibaroten, arsenic troxide) for acute promyelocytic leukemia. Int J Clin Oncol. [Review] 2007;12(5):313–7.
   PubMed Web of Science ®Google Scholar
• Scandura JM, Boccuni P, Cammenga J, Nimer SD. Transcription factor fusions in acute leukemia: variations on a theme. Oncogene [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. Review] 2002;21(21):3422–44.
   Google Scholar
• Li X, Xu YB, Wang Q, Lu Y, Zheng Y, Wang YC, et al. Leukemogenic AML1-ETO fusion protein upregulates expression of connexin 43: the role in AML 1-ETO-induced growth arrest in leukemic cells. J Cell Physiol. [Research Support, Non-U.S. Gov't] 2006;208(3):594–601.
   Google Scholar
• Liu S, Klisovic RB, Vukosavljevic T, Yu J, Paschka P, Huynh L, et al. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells. J Pharmacol Exp Ther. [Research Support, N.I.H., Extramural] 2007;321(3):953–60.
   PubMed Web of Science ®Google Scholar
• Mitani K. Molecular mechanisms of leukemogenesis by AML1/EVI-1. Oncogene. [Review] 2004;23(24):4263–9.
   PubMed Web of Science ®Google Scholar
• Zhu YM, Zhao WL, Fu JF, Shi JY, Pan Q, Hu J, et al. NOTCH1 mutations in T-cell acute lymphoblastic leukemia: prognostic significance and implication in multifactorial leukemogenesis. Clin Cancer Res. [Research Support, Non-U.S. Gov't] 2006;12(10):3043–9.
   PubMed Web of Science ®Google Scholar
• Shih Ie M, Wang TL. Notch signaling, gamma-secretase inhibitors, and cancer therapy. Cancer Res. [Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S. Review] 2007;67(5):1879–82.
   Google Scholar
• Staal FJ, Langerak AW. Signaling pathways involved in the development of T-cell acute lymphoblastic leukemia. Haematologica [Comment Research Support, Non-U.S. Gov't] 2008;93(4):493–7.
   Google Scholar
• Lane SW, Wang YJ, Lo Celso C, Ragu C, Bullinger L, Sykes SM, et al. Differential niche and Wnt requirements during acute myeloid leukemia progression. Blood [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't] 2011;118(10):2849–56.
   Google Scholar
• Schrottner P, Leick M, Burger M. The role of chemokines in B cell chronic lymphocytic leukaemia: pathophysiological aspects and clinical impact. Ann Hematol. [Research Support, Non-U.S. Gov't Review] 2010;89(5):437–46.
   Google Scholar
• Abroun S. Chemokines in homeostasis and cancers. Cell 2007;10.
   Google Scholar
• Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood [Research Support, Non-U.S. Gov't Review] 2006;107(5):1761–7.
   Google Scholar
• Fukuda S, Onishi C, Pelus LM. Trafficking of acute leukemia cells–chemokine receptor pathways that modulate leukemia cell dissemination. 2011.
   Google Scholar
• Kittang AO, Hatfield K, Sand K, Reikvam H, Bruserud O. The chemokine network in acute myelogenous leukemia: molecular mechanisms involved in leukemogenesis and therapeutic implications. Curr Top Microbiol Immunol. [Review] 2010;341:149–72.
   PubMed Web of Science ®Google Scholar
• Busillo JM, Benovic JL. Regulation of CXCR4 signaling. Biochim Biophys Acta. [Review] 2007;1768(4):952–63.
   PubMed Web of Science ®Google Scholar
• Katoh M. Integrative genomic analyses of CXCR4: transcriptional regulation of CXCR4 based on TGFbeta, Nodal, Activin signaling and POU5F1, FOXA2, FOXC2, FOXH1, SOX17, and GFI1 transcription factors. Int J Oncol. 2010;36(2):415–20.
   PubMed Web of Science ®Google Scholar
• Babashah S, Soleimani M. The oncogenic and tumour suppressive roles of microRNAs in cancer and apoptosis. Eur J Cancer. [Review] 2011;47(8):1127–37.
   PubMed Web of Science ®Google Scholar
• Garg M. MicroRNAs, stem cells and cancer stem cells. World J Stem Cells. 2012;4(7):62–70.
   PubMedGoogle Scholar
• Valastyan S, Weinberg RA. Roles for microRNAs in the regulation of cell adhesion molecules. J Cell Sci. 2011;124(7):999–1006.
   PubMed Web of Science ®Google Scholar
• Babashah S, Sadeghizadeh M, Tavirani MR, Farivar S, Soleimani M. Aberrant microRNA expression and its implications in the pathogenesis of leukemias. Cell Oncol (Dordr). [Research Support, Non-U.S. Gov't] 2012;35(5):317–34.
   PubMed Web of Science ®Google Scholar
• Sionov RV. MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies. ISRN Hematol. 2013; doi: 10.1155/2013/348212.
   PubMedGoogle Scholar
• Hatzimichael E, Georgiou G, Benetatos L, Briasoulis E. Gene mutations and molecularly targeted therapies in acute myeloid leukemia. Am J Blood Res. 2013;3(1):29–51.
   PubMedGoogle Scholar